Alyeska Investment Group
KYTX icon

Alyeska Investment Group’s Kyverna Therapeutics KYTX Stock Holding History

Alyeska Investment Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-600,000
Closed -$5.64M – 765
2025
Q4 		$5.64M Buy
+600,000
New +$4.45M 0.02% 444
2025
Q1 		– Sell
-45,000
Closed -$168K – 681
2024
Q4 		$168K Hold
45,000
– – ﹤0.01% 535
2024
Q3 		$220K Sell
45,000
-45,000
-50% -$347K ﹤0.01% 503
2024
Q2 		$675K Buy
90,000
+25,000
+38% +$382K ﹤0.01% 489
2024
Q1 		$1.61M Buy
+65,000
New +$1.81M 0.01% 389

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Alyeska Investment Group's KYTX Position: Q1 2026 in Review

Alyeska Investment Group sold out of Kyverna Therapeutics (KYTX) in Q1 2026, closing a stake of 600,000 shares — an estimated $5.64M sold.

Alyeska Investment Group first reported a position in KYTX in Q1 2024 and held it in 5 quarters. The position peaked at $5.64M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Alyeska Investment Group reported no remaining Kyverna Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 600,000 Kyverna Therapeutics shares in Q1 2026, an estimated $5.64M.
  • Alyeska Investment Group first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 5 quarters.
  • Alyeska Investment Group's Kyverna Therapeutics position peaked at $5.64M in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.